Zhejiang Taimei Medical Technology Co., Ltd. (2576) released supplemental information regarding a discloseable transaction announced on December 24, 2025. The company has formed a partnership with an initial total capital contribution of RMB227.27 million, determined through arm’s length negotiations based on commercial and legal factors.

The partnership will focus on acquiring pipeline interests in early-stage clinical trials. Based on average Phase I clinical trial costs of approximately US$5 million, it is expected to cover five to six investment projects in the healthcare industry. Each project must remain below 20% of the total partnership capital.

The group, including Zhejiang Taimei Medical Technology and its subsidiary, will contribute RMB100.00 million, representing about 44.00% of the total. Another notable partner, Jiaxing Industrial Fund, also plans to invest RMB100.00 million, aiming to attract biopharmaceutical projects to the Jiaxing region. The partnership intends to leverage an “AI + Clinical Research + Investment” ecosystem to pursue its investment strategy.

According to the announcement, the chosen distribution structure returns the original capital first, includes a 6% per annum threshold profit, and then distributes remaining returns based on actual contribution ratios. As of the date of the supplemental announcement, the partnership has not identified any specific investment targets, and no concrete deployment plan has been outlined for its capital.

The fund manager overseeing the partnership specializes in TMT and healthcare investments, with a total managed scale exceeding RMB5.00 billion. The board stated that the basis for determining the initial capital contribution remains commercially reasonable and aligns with expected synergy opportunities in clinical research technologies and services.